Lipoprotein(a) Particle Core Remodeling and Apolipoprotein C-III Inhibition
JACC: Basic to Translational Science · 2026-10 · 11 (10) · 101697
DOI: 10.1016/j.jacbts.2026.101697 ↗Kurz gefasst
Editorial in der Zeitschrift JACC: Basic to Translational Science, 2026-10. Verfasst von Dick C Chan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Western Australia, Perth, Australia. Electronic address: dick.chan@uwa.edu.au. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
ipoprotein(a) (Lp(a)) is an established, geneti- cally determined risk factor for atherosclerotic cardiovascular disease (ASCVD), myocardial infarction, and calcific aortic valve stenosis.1 Its atherogenicity is multifaceted, primarily driven by elevated particle numbers and the structural properties of apolipoprotein(a) (apo(a)), including high content of proinflammatory oxidized phospholipids (OxPLs). 1 Although human Lp(a) metabolism remains incompletely understood, emerging evidence highlights complex metabolic and structural interactions of Lp(a) with triglyceride-rich lipoproteins (TRLs), including very-low-density lipoprotein (VLDL), chylomicrons, and their remnants.2 Understanding the metabolism of Lp(a) in hypertriglyceridemic states is important to advancing our understanding of its role in ASCVD.Standard lipid-lowering therapies for hypertriglyceridemia (HTG), including fibrates and omega-3 fatty acid supplementation, can reduce plasma triglyceride concentrations by up to 30%, whereas insulin sensitizers (eg, pioglitazone) and GLP-1 receptor agonists exert more modest effects (10%-20% reduction).3 Each of these agents lowers apolipoprotein C-III (apoC-III) to varying degrees via distinct mechanisms.Emerging therapies targeting APOC3 achieve far greater triglyceride reductions and
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical School, University of Western Australia, Perth, Australia. Electronic address: dick.chan@uwa.edu.au.
- Medical School, University of Western Australia, Perth, Australia; Department of Cardiology and Internal Medicine, Cardiometabolic Clinic, Royal Perth Hospital, Perth, Australia.
Zitieren
APA
Chan, D. C., & Watts, G. F. (2026). Lipoprotein(a) Particle Core Remodeling and Apolipoprotein C-III Inhibition. JACC: Basic to Translational Science, 11(10), 101697. https://doi.org/10.1016/j.jacbts.2026.101697
Vancouver
Chan DC, Watts GF. Lipoprotein(a) Particle Core Remodeling and Apolipoprotein C-III Inhibition. JACC: Basic to Translational Science. 2026;11(10):101697. doi:10.1016/j.jacbts.2026.101697
BibTeX
@article{Chan2026,
author = {Chan, Dick C and Watts, Gerald F},
title = {Lipoprotein(a) Particle Core Remodeling and Apolipoprotein C-III Inhibition},
journal = {JACC: Basic to Translational Science},
year = {2026},
volume = {11},
number = {10},
pages = {101697},
doi = {10.1016/j.jacbts.2026.101697}
}
EUVIMED